There's always the potential that a promising mid-cap company gets bought out. Larger companies are often looking for ways to expand their opportunities and complement their existing operations. And for less than $10 billion, acquiring a mid-cap company can be an easier option than developing new competencies in-house or trying to compete against an already-successful business. 

Two modestly valued healthcare companies that I can see being bought out within the next five years are Maravai LifeSciences (NASDAQ: MRVI) and GoodRx Holdings (NASDAQ: GDRX). Here's why both could be attractive acquisition targets.

Maravai LifeSciences helps companies making messenger RNA (mRNA) therapeutics and vaccines. The highly successful mRNA-based COVID-19 vaccines from Moderna and Pfizer put a spotlight on mRNA, and that could open up more opportunities in the future.

Continue reading

Source Fool.com